FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1998712727> ?p ?o ?g. }

• W1998712727 endingPage "1421" @default.
• W1998712727 startingPage "1414" @default.
• W1998712727 abstract "2',3'-Dideoxycytidine (DDC) was evaluated for prophylactic antiviral activity in vitro and in vivo, using the feline leukemia virus (FeLV)-cat animal model. In vitro antiviral activity of DDC against FeLV was dependent upon the target cell used for infection. DDC (5 to 10 microM) inhibited FeLV infection of feline lymphoid cells by greater than 80%, while 6.07 to 12.13 microM DDC was required to similarly inhibit infection of feline fibroblasts. However, 43 to 384 microM DDC was needed to inhibit FeLV infection of primary bone marrow cells by greater than 80%. These in vitro results suggest that, although relatively low doses of DDC may be adequate to prevent infection of feline lymphoid cells, 8- to 80-times-higher doses may be necessary to block infection of bone marrow cells, a primary target cell type for FeLV infection. In vivo studies with DDC consisted of pharmacokinetic and toxicity determinations and evaluation of the prophylactic antiviral activity against FeLV in cats. Clearance and half-life values for DDC in cats were 6.5 ml/min per kg and 54.7 min, respectively. In the prophylactic studies, DDC was administered by continuous intravenous infusion at doses of 22, 15, 10, and 5 mg/kg per h for 28 days in most animals. Cats were challenged intravenously with FeLV 1 to 3 days after drug treatment began. Doses of 22 and 15 mg/kg per h were extremely toxic, causing death in 8 of 10 cats. The mg/kg per h dose was slightly toxic, causing chronic progressive thrombocytopenia over the 28-day treatment period. Of 10 cats given 10 to 5 mg of DDC per kg per h, only one was completely protected from FeLV antigenemia. However, conversion to positive FeLV antigenemia status was delayed by 2 to 7 weeks in seven of nine remaining animals. Interestingly, FeLV infection of bone marrow cells, as indicated by FELV antigen in peripheral blood neutrophils, was only slightly delayed by 0 to 2 weeks, except in the case of the one protected cat, and usually preceded conversion to antigenemia. This pattern of neutrophils becoming antigen positive before detection of antigenemia was not seen in FeLV challenge control animals and indicates that the antiviral activity of DDC may be incomplete during DDC treatment. Results of our in vitro and in vivo studies suggest that feline bone marrow cells may remain partially susceptible to FeLV infection at tolerated doses, while other somatic target tissues (i.e., lymphoid or epithelial tissues) may be protected from infection. Incomplete inhibition of FeLV infection permitted focal bone marrow infection to develop in cats given DDC. These loci of infection served as virus reservoirs which, subsequent to discontinuation of DDC treatment, permitted spread of infection to tissues previously protected during treatment." @default.
• W1998712727 created "2016-06-24" @default.
• W1998712727 creator A5004440413 @default.
• W1998712727 creator A5010712036 @default.
• W1998712727 creator A5011268842 @default.
• W1998712727 creator A5028863815 @default.
• W1998712727 creator A5048383959 @default.
• W1998712727 creator A5049764854 @default.
• W1998712727 creator A5066758755 @default.
• W1998712727 creator A5089975128 @default.
• W1998712727 date "1990-07-01" @default.
• W1998712727 modified "2023-09-27" @default.
• W1998712727 title "In vitro and in vivo evidence that the antiviral activity of 2',3'-dideoxycytidine is target cell dependent in a feline retrovirus animal model" @default.
• W1998712727 cites W1492962073 @default.
• W1998712727 cites W1495176279 @default.
• W1998712727 cites W1557880692 @default.
• W1998712727 cites W1963848480 @default.
• W1998712727 cites W1964229718 @default.
• W1998712727 cites W1981342096 @default.
• W1998712727 cites W1983732112 @default.
• W1998712727 cites W1991249891 @default.
• W1998712727 cites W1997685222 @default.
• W1998712727 cites W2007394757 @default.
• W1998712727 cites W2012667372 @default.
• W1998712727 cites W2021647664 @default.
• W1998712727 cites W2028013028 @default.
• W1998712727 cites W2085459671 @default.
• W1998712727 cites W2090463993 @default.
• W1998712727 cites W2092719343 @default.
• W1998712727 cites W2093943927 @default.
• W1998712727 cites W2102973576 @default.
• W1998712727 cites W2112362416 @default.
• W1998712727 cites W2139727555 @default.
• W1998712727 cites W2171775661 @default.
• W1998712727 cites W2199723138 @default.
• W1998712727 cites W2259145987 @default.
• W1998712727 cites W2091700060 @default.
• W1998712727 doi "https://doi.org/10.1128/aac.34.7.1414" @default.
• W1998712727 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/175992" @default.
• W1998712727 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2167039" @default.
• W1998712727 hasPublicationYear "1990" @default.
• W1998712727 type Work @default.
• W1998712727 sameAs 1998712727 @default.
• W1998712727 citedByCount "16" @default.
• W1998712727 countsByYear W19987127272013 @default.
• W1998712727 countsByYear W19987127272015 @default.
• W1998712727 countsByYear W19987127272020 @default.
• W1998712727 countsByYear W19987127272021 @default.
• W1998712727 crossrefType "journal-article" @default.
• W1998712727 hasAuthorship W1998712727A5004440413 @default.
• W1998712727 hasAuthorship W1998712727A5010712036 @default.
• W1998712727 hasAuthorship W1998712727A5011268842 @default.
• W1998712727 hasAuthorship W1998712727A5028863815 @default.
• W1998712727 hasAuthorship W1998712727A5048383959 @default.
• W1998712727 hasAuthorship W1998712727A5049764854 @default.
• W1998712727 hasAuthorship W1998712727A5066758755 @default.
• W1998712727 hasAuthorship W1998712727A5089975128 @default.
• W1998712727 hasBestOaLocation W19987127271 @default.
• W1998712727 hasConcept C112705442 @default.
• W1998712727 hasConcept C126322002 @default.
• W1998712727 hasConcept C150903083 @default.
• W1998712727 hasConcept C159047783 @default.
• W1998712727 hasConcept C202751555 @default.
• W1998712727 hasConcept C203014093 @default.
• W1998712727 hasConcept C207001950 @default.
• W1998712727 hasConcept C2522874641 @default.
• W1998712727 hasConcept C2779692357 @default.
• W1998712727 hasConcept C2779904517 @default.
• W1998712727 hasConcept C2780007613 @default.
• W1998712727 hasConcept C2780216070 @default.
• W1998712727 hasConcept C2780727368 @default.
• W1998712727 hasConcept C2780866839 @default.
• W1998712727 hasConcept C29730261 @default.
• W1998712727 hasConcept C55493867 @default.
• W1998712727 hasConcept C71924100 @default.
• W1998712727 hasConcept C86803240 @default.
• W1998712727 hasConcept C98274493 @default.
• W1998712727 hasConceptScore W1998712727C112705442 @default.
• W1998712727 hasConceptScore W1998712727C126322002 @default.
• W1998712727 hasConceptScore W1998712727C150903083 @default.
• W1998712727 hasConceptScore W1998712727C159047783 @default.
• W1998712727 hasConceptScore W1998712727C202751555 @default.
• W1998712727 hasConceptScore W1998712727C203014093 @default.
• W1998712727 hasConceptScore W1998712727C207001950 @default.
• W1998712727 hasConceptScore W1998712727C2522874641 @default.
• W1998712727 hasConceptScore W1998712727C2779692357 @default.
• W1998712727 hasConceptScore W1998712727C2779904517 @default.
• W1998712727 hasConceptScore W1998712727C2780007613 @default.
• W1998712727 hasConceptScore W1998712727C2780216070 @default.
• W1998712727 hasConceptScore W1998712727C2780727368 @default.
• W1998712727 hasConceptScore W1998712727C2780866839 @default.
• W1998712727 hasConceptScore W1998712727C29730261 @default.
• W1998712727 hasConceptScore W1998712727C55493867 @default.
• W1998712727 hasConceptScore W1998712727C71924100 @default.
• W1998712727 hasConceptScore W1998712727C86803240 @default.
• W1998712727 hasConceptScore W1998712727C98274493 @default.
• W1998712727 hasIssue "7" @default.
• W1998712727 hasLocation W19987127271 @default.

• next